Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.37
+10.56 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
3 Tips for Coronavirus Investing Right Now
July 05, 2021
Whether you're a cautious or aggressive investor, there's something for you in this space.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs
July 02, 2021
A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug...
Via
Benzinga
Facebook And Nvidia Lead The QQQ Thursday
July 01, 2021
U.S. indices are trading higher following better-than-expected jobless claims, which lifted recovery sentiment to start off July. ...
Via
Benzinga
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
June 30, 2021
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,...
Via
Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
June 30, 2021
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Via
The Motley Fool
Exposures
COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
June 29, 2021
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...
Via
Benzinga
Exposures
COVID-19
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
June 29, 2021
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
June 29, 2021
Upgrades For Nutrien Ltd (NYSE:
Via
Benzinga
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
June 29, 2021
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I...
Via
Benzinga
Intellia Seeks To Raise $400M Via Equity
June 29, 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to...
Via
Benzinga
Facebook And Nvidia Lead The QQQ Higher Monday
June 28, 2021
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve...
Via
Benzinga
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
June 28, 2021
Find out why these stocks are climbing higher.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Intellia Therapeutics Stock Is Skyrocketing Today
June 28, 2021
The company reported promising interim trial results for its CRISPR gene-editing candidate.
Via
The Motley Fool
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
June 28, 2021
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.
Via
Investor's Business Daily
Why Intellia Therapeutics Stock Is Soaring Today
June 28, 2021
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi...
Via
Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
June 28, 2021
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.
Via
InvestorPlace
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
June 28, 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1...
Via
Benzinga
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
June 25, 2021
The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two...
Via
Benzinga
3 Companies With Low Debt to Buy in Case Interest Rates Rise
June 23, 2021
These companies are generating tons of free cash and don't need to rely on debt to grow.
Via
The Motley Fool
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
June 25, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
June 22, 2021
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ...
Via
Benzinga
Exposures
COVID-19
3 Bargain Stocks You Can Buy Today
June 21, 2021
The market is mispricing these names, ignoring the long-term growth prospects ahead for each of them.
Via
The Motley Fool
How This Pharma Company Can Benefit From Its Competitors
June 20, 2021
Delays in FDA approval for Incyte could spell good news for Sanofi.
Via
The Motley Fool
Exposures
Product Safety
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
June 18, 2021
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...
Via
Talk Markets
BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial
June 18, 2021
BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates the therapeutic cancer...
Via
Benzinga
Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
June 17, 2021
Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to treat COVID-19 and other...
Via
Benzinga
Exposures
COVID-19
Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More
June 17, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't...
Via
Benzinga
Elanco Is Looking To Challenge Zoetis, Will The $440 Million Kindred Buyout Help?
June 16, 2021
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring.
Via
Investor's Business Daily
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds
June 16, 2021
Regeneron Pharmaceutical Inc.’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.